{
    "clinical_study": {
        "@rank": "67308", 
        "arm_group": [
            {
                "arm_group_label": "TRN-157", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "This single ascending dose study is to determine and evaluate the safety and tolerability of\n      TRN-157 in approximately 40 healthy subjects."
        }, 
        "brief_title": "Single Ascending Dose Study of TRN-157 in Healthy Subjects", 
        "completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Chronic Obstructive Pulmonary Disease", 
        "condition_browse": {
            "mesh_term": [
                "Lung Diseases", 
                "Respiration Disorders", 
                "Pulmonary Disease, Chronic Obstructive", 
                "Lung Diseases, Obstructive"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Subject has provided written informed consent\n\n          2. The subject is male or female 18 to 65 years of age\n\n          3. If the subject or subject's partner is of childbearing potential, a medically\n             acceptable form of contraception will be\n\n          4. Non-smoker\n\n          5. Good general health\n\n          6. Willing to abstain from alcohol, caffeine, and xanthine-containing beverages\n\n          7. The subject is compliant and available throughout the entire study period\n\n        Exclusion Criteria:\n\n          1. Current diagnosis, as per subject or investigator or screening assessment, of:\n\n               1. unstable or uncontrolled disease in any organ system (including cardiovascular)\n                  on present therapy\n\n               2. history of narrow angle glaucoma\n\n               3. history of alcohol abuse within the past 5 years\n\n               4. history of smoking within the past 6 months\n\n               5. positive result for the alcohol and/or drugs of abuse\n\n               6. weight > 100 kg or < 50 kg\n\n               7. clinically significant abnormal ECG\n\n               8. history of clinically significant (per the Investigator) disease or disorder\n\n               9. any clinically significant abnormalities in clinical chemistry, hematology, or\n                  urinalysis results\n\n              10. Abnormal vital signs defined as any of the following:\n\n                    -  Systolic blood pressure \u2265 140 mmHg\n\n                    -  Diastolic blood pressure \u2265 90mmHg\n\n          2. Heart rate < 40 or > 85 beats per minute\n\n          3. Fever or other clinically significant physical exam findings\n\n          4. Current or history of clinically significant respiratory disease, including asthma,\n             emphysema, chronic bronchitis, or cystic fibrosis\n\n          5. History or current symptom(s) of respiratory tract inflammation\n\n          6. Inability to perform reproducible spirometry in accordance with American  Thoracic\n             Society (ATS) guidelines\n\n          7. Abnormal FEV1, FVC, or FEV1/FVC (FEV1 or FVC < 80% of predicted or FEV1/FVC ratio <\n             0.7)\n\n          8. FEV1 variability > 10% between study visits\n\n          9. Female of childbearing potential with a positive serum pregnancy test or currently\n             breastfeeding\n\n         10. Currently being treated for hypertension or taking any other medications that affect\n             blood pressure significantly\n\n         11. Inability to perform acceptable, quality serial spirometry or any other study\n             procedures\n\n         12. Positive screen for Hepatitis B surface antigen (HBsAg), Hepatitis C antibody, or HIV\n             antibody"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 5, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02133339", 
            "org_study_id": "TRN-157-101"
        }, 
        "intervention": [
            {
                "arm_group_label": "TRN-157", 
                "intervention_name": "TRN-157", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 7, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Cypress", 
                    "country": "United States", 
                    "state": "California"
                }
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase I, Randomized, Double-blind, Placebo Controlled, Single Ascending Dose Study to Evaluate the Safety and Tolerability of Nebulized, TRN-157 Inhalation Solution in Healthy Subjects", 
        "overall_contact": {
            "email": "jdiehl@theronpharma.com", 
            "last_name": "Janet Diehl", 
            "phone": "866-585-7823", 
            "phone_ext": "102"
        }, 
        "overall_official": {
            "affiliation": "Theron Pharmaceuticals, Inc.", 
            "last_name": "Joe Oren", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Safety and tolerability as determined by number of subjects with adverse events", 
            "safety_issue": "Yes", 
            "time_frame": "1 week"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02133339"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Area Under the Plasma Concentration-Time Curve from Zero to the Time of the Last Measurable Concentration (AUC0-t)", 
                "measure": "Determination of pharmacokinetic parameters", 
                "safety_issue": "Yes", 
                "time_frame": "1 week"
            }, 
            {
                "description": "Area Under the Plasma Concentration-Time Curve from Zero to Infinity (AUC0-inf)", 
                "measure": "Determination of pharmacokinetic parameters", 
                "safety_issue": "Yes", 
                "time_frame": "1 week"
            }, 
            {
                "description": "Peak Plasma Concentration (Cmax)", 
                "measure": "Determination of pharmacokinetic parameters", 
                "safety_issue": "Yes", 
                "time_frame": "1 week"
            }, 
            {
                "description": "Time to Peak Plasma Concentration (tmax)", 
                "measure": "Determination of pharmacokinetic parameters", 
                "safety_issue": "Yes", 
                "time_frame": "1 week"
            }, 
            {
                "description": "Half-Life (t\u00bd)", 
                "measure": "Determination of pharmacokinetic parameters", 
                "safety_issue": "Yes", 
                "time_frame": "1 week"
            }, 
            {
                "description": "Elimination Rate Constant (kel)", 
                "measure": "Determination of pharmacokinetic parameters", 
                "safety_issue": "Yes", 
                "time_frame": "1 week"
            }, 
            {
                "description": "Volume of Distribution at Steady State after Non-IV Administration (Vss/F)", 
                "measure": "Determination of pharmacokinetic parameters", 
                "safety_issue": "Yes", 
                "time_frame": "1 week"
            }, 
            {
                "description": "Total Plasma Clearance after Non-IV Administration (CL/F)", 
                "measure": "Determination of pharmacokinetic parameters", 
                "safety_issue": "Yes", 
                "time_frame": "1 week"
            }
        ], 
        "source": "Theron Pharmaceuticals, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Theron Pharmaceuticals, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}